Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¾Ï ȯÀÚÀÇ Áúº´ »óÅ¿¡ µû¸¥ Ç÷Áß PSAÀÇ º¯È­ A Change of Serum Prostate Specific Antigen Correlated with Clinical Status of Prostate Cancer Patient

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 6È£ p.580 ~ 584
Á¶¼º´ö, ±èÀ±È­,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶¼º´ö (  ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

±èÀ±È­ (  ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Àü¸³¼±¾ÏÀº ÀÎÁ¾¿¡ µû¸¥ Â÷ÀÌ°¡ À־ µ¿¾çÀο¡¼­´Â ¹ß»ý ºóµµ°¡ ³·À¸¸ç,1±¹³»¿¡¼­µµ ±Ø
È÷ ³·Àº »óÅ¿´À¸³ª ÃÖ±Ù ¿ì¸® ³ª¶ó¿¡¼­µµ ³ë·É Àα¸ÀÇ Áõ°¡¿Í ½Ä»ýÈ°ÀÇ ¼­±¸È­·Î Àü¸³¼±¾Ï
ȯÀÚ°¡ Á¡Â÷ Áõ°¡ÇÏ´Â Ãß¼¼¿¡ ÀÖ¾î º» Áúȯ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù. Àü¸³¼±¾ÏÀº ÁøÇà
µÈ »óÅ·Π³»¿øÇÏ´Â °æ¿ì°¡ ¸¹°í ÀÌ·¯ÇÑ °æ¿ì ÀûÀýÇÑ Ä¡·á¹ýÀÌ °³¹ßµÇÁö ¾ÊÀº »óÅÂÀÌ´Ù. µû
¶ó¼­ Àü¸³¼±¾ÏÀÇ Á¶±â¹ß°ßÀ» À§ÇÑ ³ë·ÂÀÌ ÇÊ¿äÇѵ¥ ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â °Ë»çÁ¾¸ñÀ¸·Î´Â °æ
Á÷ÀåÃÊÀ½ÆÄ °Ë»ç, Àü¸³¼±Æ¯ÀÌÇ׿ø(prostate specific antigen; PSA)ÀÌ ÀÖ´Ù. ÀÌ·¯ÇÑ Àü¸³¼±Æ¯
ÀÌ Ç׿øÀº Àü¸³¼±¾ÏÀ» ó À½ Áø´ÜÇÒ ¶§ÀÇ Áø´ÜÀû °¡Ä¡³ª, ±ÙÄ¡Àû Àü¸³¼±ÀûÃâ¼úÀ» ¹Þ°Å³ª, ¹æ
»ç¼±Ä¡·á ÈÄ Àç¹ßµÇ´Â Áúº´ »óŸ¦ ¿¹ÃøÇÏ´Â ÁöÇ¥·Î¼­´Â Ź¿ùÇÑ °¡Ä¡°¡ ÀÖ´Â °ÍÀ¸·Î À̹Ì
º¸°íµÈ ¹Ù ÀÖ´Ù. ¶ÇÇÑ Áúº´ÀÇ »óÅÂ¿Í ºñ·ÊÇÏ¿© Ç÷Áß Àü¸³¼±Æ¯ÀÌÇ׿øÀÌ Áõ°¡µÇ´Â °ÍÀ¸·Î º¸
°íµÇ¾ú´Ù. ±×·¯³ª 10%ÀÇ È¯ÀÚ¿¡¼­´Â º´±â(stage)¿Í ¹«°üÇÏ´Ù´Â º¸°íµµ ÀÖ´Ù. º» ¿¬±¸¸¦ Åë
ÇÏ¿© ÀúÀÚµéÀº º´¸®Á¶Á÷ÇÐÀûÀ¸·Î Àü¸³¼±¾ÏÀÌ È®Áø µÉ ´ç½Ã¿¡ À־ Ç÷Áß PSAÄ¡¿Í ÀÓ»óÀû
Áúº´ »óŸ¦ ºñ±³ÇÏ¿© Àü¸³¼±¾Ï ȯÀÚÀÇ Áúº´ »óŸ¦ Æò°¡Çϴµ¥ À־ Ç÷Áß Àü¸³¼±Æ¯ÀÌÇ×
¿øÀÌ °®´Â ÀÓ»óÀû ÀÇÀǸ¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : It has been reported that serum prostate specific antigen(PSA) generally
increase in direct proportion to clinical status of prostate cancer, but some reports
suggest that PSA level is not correlated with clinical stage in 10% of the patients of
prostate cancer. We evaluate the value of PSA about clinical status of prostate cancer
through comparing disease status and PSA of patient at initial diagnosis of prostate
cancer.
Materials and Methods : A clinical study was retrospectively made on sixty patients
with prostate adenocarcinoma. The patients were admitted to the Department of Urology
between January of 1992 and December of 1996. Results were obtained through
statistical analysis of the correlation between PSA level and clinical status by
performing serum PSA, chest X-ray, bone scan, pelvic CT or pelvic MRI. At the time
of the analysis patients were diagnosed with prostate adenocarcinoma pathologically.
Results : Mean PSA level of patients with bone metastasis and no metastasis was 125.4
and 97.89ng/m1, respectively and correlation between the two groups was not observed,
so bone scan could not be replaced by measuring serum PSA. The number of hot
uptake In bone scan wasn't correlated with serum PSA level. Gleason score wasn't
correlated with serum PSA level. Multiple comparisons in groups which were classified
by bone metastasis and lymphatic metastasis had no statistical significance.
Conclusions : As the result of the above observations, we predict that there is a
problem in evaluating clinical status with PSA as compared with the value at initial
diagnosis or as a predictor of recurrence in patients with radical prostatectomy. (Korean
J Urol 1998; 39: 580¡­4)

Å°¿öµå

Prostate cancer; Prostate specific antigen;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS